급성 간염 모델 신청 : 시각화와 간장 Microcirculation의 혈류와 산소 소비 분석

Executive Industry Relevance

This optical method enables direct visualization and quantification of hepatic microcirculation and oxygen gradients, providing mechanistic insights into liver disease pathophysiology. By linking hemodynamic changes to enzyme expression patterns and zonation-specific injury, it supports target validation in hepatotoxicity and metabolic disease models. The approach offers a translational bridge from discovery to preclinical evaluation by revealing early functional alterations in liver microcirculation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by correlating oxygen gradient alterations with zonated enzyme expression and pathology.
• Operational Value: Enables functional target validation through real-time, label-based hemodynamic readouts in disease models.
• Predictive Value: Supports predictive confidence by identifying early shifts in oxygen consumption that precede structural damage.

Screening & Assay Development

• Assay Readiness: Prepares validated biological systems with quantifiable oxygen and flow parameters for compound screening.
• Reproducibility: Delivers continuous, non-contact measurements that standardize hemodynamic assessments across studies.
• Platform Utility: Generates scalable outputs (vessel diameter, flow velocity, pO2) suitable for high-content analysis workflows.

Translational & Preclinical Research

• Disease Relevance: Models acute hepatitis by demonstrating how pericentral necrosis alters oxygen gradients and downstream metabolic signaling.
• Translational Continuity: Connects microvascular dysfunction to enzyme expression shifts, supporting biomarker-aligned pathway analysis.
• Risk-Adjusted Decisions: Enables early detection of hemodynamic changes that inform go/no-go progression in preclinical pipelines.

Pipeline & Workflow Integration

The method integrates into discovery workflows by providing functional hemodynamic data that informs target engagement and pathway modulation studies prior to lead optimization.

• Discovery Biology: Supports hypothesis testing by linking portal-to-central oxygen gradients to metabolic zonation and enzyme activity.
• Screening: Delivers quantitative outputs (flow velocity, vessel diameter, pO2) that enable compound effect stratification in liver models.
• Analytics: Provides decay-time-based oxygen measurements and flow metrics that facilitate comparative condition analysis.
• Translational Research: Connects hemodynamic shifts to zonated pathology, supporting biomarker alignment in preclinical validation.
• Enterprise Reuse: Establishes a reusable optical platform for longitudinal monitoring of liver microcirculation across disease models.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by directly measuring oxygen gradients that drive hepatic zonation and enzyme expression.
• Operational Value: Ensures standardization through non-contact, continuous optical measurement independent of probe loading variability.
• Strategic Value: Improves go/no-go decisions by identifying early hemodynamic biomarkers of liver injury before histologic endpoints.
• Portfolio Impact: Enables risk-adjusted prioritization by revealing oxygen consumption changes predictive of zonated toxicity.

Implementation Considerations

• Requires expertise in intravital microscopy, fluorescent labeling, and phosphorescence lifetime imaging.
• Depends on laser systems with specific wavelength excitation (e.g., 532 nm second harmonic) and sensitive red-shifted detection (PMT ~700 nm).
• Necessitates cross-team standardization for consistent calibration using defined pO2 references (0 and 150 mmHg) under controlled pH and temperature.
• Involves adaptation considerations when extending to other microvascular beds due to differences in flow dynamics and oxygen solubility.
• Includes practical limitations such as signal attenuation in deeply embedded vessels and the need for surgical access to hepatic tissue.

Biopharma FAQs